Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...

Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst ...

Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Thursday, March 13th. Roth Capital analyst J.

StockNews.com lowered shares of Globus Medical (NYSE:GMED – Free Report) from a buy rating to a hold rating in a research ...

AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology ...

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced ...

Monogram Technologies (Nasdaq:MGRM) announced today that it received FDA 510(k) clearance for its mBôs total knee ...